Evidence map›Paper›PMID 23935495›Full record

ArticlePLoS pathogens2013

Discovery of anthelmintic drug targets and drugs using chokepoints in nematode metabolic pathways.

Christina M Taylor, Qi Wang, Bruce A Rosa, Stanley Ching-Cheng Huang, Kerrie Powell, Tim Schedl, Edward J Pearce, Sahar Abubucker, Makedonka Mitreva

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
6.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 98 citations in OpenAlex.

  1. Discovery of novel repurposed anthelminthics againstCurrent research in parasitology & vector-borne diseases · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Metabolite profiling ofFrontiers in cellular and infection microbiology · 2023
    Article
  10. Article
  11. Tandem Mass Tagging (TMT) Reveals Tissue-Specific Proteome of L4 Larvae ofInternational journal of molecular sciences · 2022
    Article
  12. Parasite OMICS, the grand challenges ahead.Frontiers in parasitology · 2022
    Article
  13. Article
  14. Article
  15. Rapid determination of nematode cell and organ susceptibility to toxic treatments.International journal for parasitology. Drugs and drug resistance · 2020
    Article
  16. Article
  17. Article
  18. In Vitro Anthelmintic Evaluation ofMolecules (Basel, Switzerland) · 2020
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Christina M TaylorThe Genome Institute, Washington University School of Medicine, St. Louis, Missouri, United States of America.
Qi Wang
Bruce A Rosa
Stanley Ching-Cheng Huang
Kerrie Powell
Tim Schedl
Edward J Pearce
Sahar Abubucker
Makedonka Mitreva
Washington University in St. Louis · USScynexis (United States) · US

Funding

Stem cell versus meiotic fate decision in C. elegansR01GM100756 · NIGMS · WASHINGTON UNIVERSITY · PI SCHEDL, TIM · 2012 to 2023
$4.2M
COMPARATIVE GENOMICS OF PARASITIC NEMATODESR01AI081803 · NIAID · WASHINGTON UNIVERSITY · PI MITREVA, MAKEDONKA · 2009 to 2018
$3.1M
COMPARATIVE GENOMICS OF PARASITIC NEMATODESR56AI081803 · NIAID · WASHINGTON UNIVERSITY · PI MITREVA, MAKEDONKA · 2019 to 2019
$697k
NIAID NIH HHS AI081803NIAID NIH HHS R01 AI081803NIAID NIH HHS R56 AI081803NIGMS NIH HHS R01 GM100756
6 · The paper itself

Abstract

Parasitic roundworm infections plague more than 2 billion people (1/3 of humanity) and cause drastic losses in crops and livestock. New anthelmintic drugs are urgently needed as new drug resistance and environmental concerns arise. A "chokepoint reaction" is defined as a reaction that either consumes a unique substrate or produces a unique product. A chokepoint analysis provides a systematic method of identifying novel potential drug targets. Chokepoint enzymes were identified in the genomes of 10 nematode species, and the intersection and union of all chokepoint enzymes were found. By studying and experimentally testing available compounds known to target proteins orthologous to nematode chokepoint proteins in public databases, this study uncovers features of chokepoints that make them successful drug targets. Chemogenomic screening was performed on drug-like compounds from public drug databases to find existing compounds that target homologs of nematode chokepoints. The compounds were prioritized based on chemical properties frequently found in successful drugs and were experimentally tested using Caenorhabditis elegans. Several drugs that are already known anthelmintic drugs and novel candidate targets were identified. Seven of the compounds were tested in Caenorhabditis elegans and three yielded a detrimental phenotype. One of these three drug-like compounds, Perhexiline, also yielded a deleterious effect in Haemonchus contortus and Onchocerca lienalis, two nematodes with divergent forms of parasitism. Perhexiline, known to affect the fatty acid oxidation pathway in mammals, caused a reduction in oxygen consumption rates in C. elegans and genome-wide gene expression profiles provided an additional confirmation of its mode of action. Computational modeling of Perhexiline and its target provided structural insights regarding its binding mode and specificity. Our lists of prioritized drug targets and drug-like compounds have potential to expedite the discovery of new anthelmintic drugs with broad-spectrum efficacy.

Indexed as

Databases, ProteinDrug DiscoveryHelminth ProteinsNematode InfectionsAnimalsAnthelminticsDrosophila melanogasterHumansNematodaOxygen ConsumptionAnthelminticsHelminth Proteins

Identifiers

PMID23935495
PMCPMC3731235
OpenAlexW1970097556

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.